M8168
4-Methylumbelliferyl phosphate disodium salt
phosphatase substrate, ≥98% (TLC), powder
Synonym(s):
4-MUP, Disodium 4-methylumbelliferyl phosphate
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C10H7Na2O6P
CAS Number:
Molecular Weight:
300.11
NACRES:
NA.32
PubChem Substance ID:
UNSPSC Code:
12352204
EC Number:
245-325-0
MDL number:
Product Name
4-Methylumbelliferyl phosphate disodium salt, phosphatase substrate
Quality Level
assay
≥98% (TLC)
form
powder
solubility
water: 50 mg/mL, clear, colorless
fluorescence
λex 319 nm; λem 384 nm (pH 9.0), λex 360 nm; λem 449 nm (Reaction product)
storage temp.
−20°C
SMILES string
[Na+].[Na+].CC1=CC(=O)Oc2cc(OP([O-])([O-])=O)ccc12
InChI
1S/C10H9O6P.2Na/c1-6-4-10(11)15-9-5-7(2-3-8(6)9)16-17(12,13)14;;/h2-5H,1H3,(H2,12,13,14);;/q;2*+1/p-2
InChI key
WUUDJQVNZPEPKN-UHFFFAOYSA-L
General description
Fluorogenic substrate for phosphatases.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Product Information Sheet
Rubhana Raqib et al.
BMC infectious diseases, 12, 111-111 (2012-05-12)
Treatment of shigellosis in rabbits with butyrate reduces clinical severity and counteracts the downregulation of cathelicidin (CAP-18) in the large intestinal epithelia. Here, we aimed to evaluate whether butyrate can be used as an adjunct to antibiotics in the treatment
Lucia A de Oliveira Fraga et al.
BMC immunology, 11, 56-56 (2010-11-17)
During the pre-patent stage of infection, juvenile Schistosoma blood flukes co-opt signals from the adaptive immune system to facilitate parasite development, but the types of responses that are induced at this early stage of infection, and the parasite antigens they
Giulia Pavani et al.
Nature communications, 11(1), 3778-3778 (2020-07-31)
Targeted genome editing has a great therapeutic potential to treat disorders that require protein replacement therapy. To develop a platform independent of specific patient mutations, therapeutic transgenes can be inserted in a safe and highly transcribed locus to maximize protein